2024 Q3 Form 10-Q Financial Statement

#000149315224036960 Filed on September 18, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $329.6K $74.15K $161.8K
YoY Change 197.92% -66.3% -38.57%
Operating Profit -$329.6K -$74.15K
YoY Change 197.93% -66.89%
Interest Expense $473.7K $466.3K $458.8K
YoY Change -38.72% -32.42% -46.58%
% of Operating Profit
Other Income/Expense, Net $473.7K $466.3K $458.8K
YoY Change -38.71% -32.46% -46.58%
Pretax Income $144.1K $392.2K $297.0K
YoY Change -78.24% -15.92% -50.12%
Income Tax
% Of Pretax Income
Net Earnings $144.1K $392.2K $297.0K
YoY Change -78.24% -15.92% -50.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.07 -$0.03 -$0.05
COMMON SHARES
Basic Shares Outstanding 6.407M shares 6.407M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $29.10K $45.60K $600.00
Receivables
Other Receivables
Total Short-Term Assets $29.10K $45.60K $600.00
YoY Change -99.95% -99.92% -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $37.26M $36.68M $36.07M
YoY Change 3725798000.0% -676931.0% -3606792800.0%
TOTAL ASSETS
Total Short-Term Assets $29.10K $45.60K $600.00
Total Long-Term Assets $37.26M $36.68M $36.07M
Total Assets $37.29M $36.73M $36.07M
YoY Change -38.68% -38.26% -38.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $408.8K $330.3K $404.8K
YoY Change 34.69% 13.6% 40.01%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.939M $3.526M $3.257M
YoY Change -25.74% -24.2% -17.7%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.875M $2.875M $2.875M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.939M $3.526M $3.257M
Total Long-Term Liabilities $2.875M $2.875M $2.875M
Total Liabilities $6.814M $6.401M $6.132M
YoY Change 28.46% 37.61% 54.94%
SHAREHOLDERS EQUITY
Retained Earnings -$6.788M -$6.309M -$6.085M
YoY Change 28.44% 36.76% 58.96%
Common Stock $3.205K $3.205K $3.205K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.785M -$6.306M -$6.081M
YoY Change
Total Liabilities & Shareholders Equity $37.29M $36.73M $36.07M
YoY Change -38.68% -38.26% -38.17%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $144.1K $392.2K $297.0K
YoY Change -78.24% -15.92% -50.12%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $0.00 $0.00
YoY Change -100.0% -100.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$100.0K -$150.0K -$250.0K
YoY Change -82.19% -73.21% -100.42%
Cash From Investing Activities -$100.0K -$150.0K -$250.0K
YoY Change -82.19% -73.21% -100.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 150.0K $250.0K
YoY Change -84.37% -78.57% -100.42%
NET CHANGE
Cash From Operating Activities 0.000 0.000
Cash From Investing Activities -100.0K -150.0K -$250.0K
Cash From Financing Activities 100.0K 150.0K $250.0K
Net Change In Cash 0.000 0.000
YoY Change -100.0% -100.0%
FREE CASH FLOW
Cash From Operating Activities $0.00 $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
MSSA Increase Decrease In Due To Sponsor
IncreaseDecreaseInDueToSponsor
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
MSSA Cash Withdrawn From Trust Account To Redeem Public Shares
CashWithdrawnFromTrustAccountToRedeemPublicShares
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
usd
CY2023Q4 us-gaap Escrow Deposit
EscrowDeposit
usd
CY2024Q2 us-gaap Cash
Cash
usd
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
MSSA Increase Decrease In Due To Sponsor
IncreaseDecreaseInDueToSponsor
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
MSSA Cash Withdrawn From Trust Account To Redeem Public Shares
CashWithdrawnFromTrustAccountToRedeemPublicShares
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
usd
CY2023Q4 us-gaap Escrow Deposit
EscrowDeposit
usd
CY2024Q2 us-gaap Cash
Cash
usd
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
usd
CY2023Q4 us-gaap Escrow Deposit
EscrowDeposit
usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
dei Document Type
DocumentType
10-Q
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1875 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
45600 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1875 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
36684240 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
35359088 usd
CY2024Q2 us-gaap Assets
Assets
36729840 usd
CY2023Q4 us-gaap Assets
Assets
35360963 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
330260 usd
CY2024Q2 us-gaap Other Liabilities
OtherLiabilities
623546 usd
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
375834 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
2572403 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3526209 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2846517 usd
CY2024Q2 MSSA Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2875000 usd
CY2023Q4 MSSA Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2875000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2875000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
6401209 usd
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11500000 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6407416 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
45600 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1875 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
45600 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1875 usd
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
36684240 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
36684240 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
35359088 usd
CY2024Q2 us-gaap Assets
Assets
36729840 usd
CY2023Q4 us-gaap Assets
Assets
35360963 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
330260 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
298280 usd
CY2024Q2 us-gaap Other Liabilities
OtherLiabilities
623546 usd
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
375834 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
2572403 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2172403 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3526209 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2846517 usd
CY2024Q2 MSSA Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2875000 usd
CY2023Q4 MSSA Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2875000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2875000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2875000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
6401209 usd
CY2023Q4 us-gaap Liabilities
Liabilities
5721517 usd
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3202416 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11500000 shares
CY2024Q2 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
11.44
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
11.06
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
36634240 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3205000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3205 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3205 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6308814 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6305609 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5769642 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36729840 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35360963 usd
CY2023Q2 MSSA Formation And Operational Costs
FormationAndOperationalCosts
223977 usd
CY2024Q2 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
11.44
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
11.06
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
36634240 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3205000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3205000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3205 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6308814 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6305609 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5769642 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36729840 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35360963 usd
CY2023Q2 MSSA Formation And Operational Costs
FormationAndOperationalCosts
223977 usd
MSSA Formation And Operational Costs
FormationAndOperationalCosts
235967 usd
MSSA Formation And Operational Costs
FormationAndOperationalCosts
487395 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
74148 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
223977 usd
MSSA Formation And Operational Costs
FormationAndOperationalCosts
235967 usd
MSSA Formation And Operational Costs
FormationAndOperationalCosts
487395 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
74148 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
223977 usd
us-gaap Operating Expenses
OperatingExpenses
235967 usd
us-gaap Operating Expenses
OperatingExpenses
487395 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-74148 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-235967 usd
us-gaap Interest Income Operating
InterestIncomeOperating
770422 usd
us-gaap Interest Income Operating
InterestIncomeOperating
1307724 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
690406 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
925152 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1549326 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
392165 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
466429 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
689185 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1061931 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
466429 usd
us-gaap Net Income Loss
NetIncomeLoss
689185 usd
us-gaap Net Income Loss
NetIncomeLoss
1061931 usd
CY2024Q1 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-458839 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
297020 usd
CY2024Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension
-150000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
392165 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2803403 usd
CY2023Q1 MSSA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension
-757676 usd
CY2023Q1 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-858920 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
595502 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3824497 usd
CY2023Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension
-561466 usd
CY2023Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-690406 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
466429 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4609940 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4609940 usd
us-gaap Interest Income Operating
InterestIncomeOperating
770422 usd
us-gaap Interest Income Operating
InterestIncomeOperating
1307724 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
22125 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
65850 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
58125 usd
MSSA Increase Decrease In Due To Sponsor
IncreaseDecreaseInDueToSponsor
247712 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
31980 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
143996 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-344341 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
400000 usd
MSSA Cash Withdrawn From Trust Account To Redeem Public Shares
CashWithdrawnFromTrustAccountToRedeemPublicShares
60089158 usd
us-gaap Operating Expenses
OperatingExpenses
235967 usd
us-gaap Operating Expenses
OperatingExpenses
487395 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-74148 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-223977 usd
CY2023Q2 us-gaap Interest Income Operating
InterestIncomeOperating
448804 usd
us-gaap Interest Income Operating
InterestIncomeOperating
770422 usd
us-gaap Interest Income Operating
InterestIncomeOperating
1307724 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
690406 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
925152 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
689185 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
392165 usd
us-gaap Net Income Loss
NetIncomeLoss
689185 usd
us-gaap Net Income Loss
NetIncomeLoss
1061931 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5769642 usd
CY2024Q1 MSSA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension
-150000 usd
CY2024Q1 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-458839 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
297020 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-6081461 usd
CY2024Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension
-150000 usd
CY2024Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-466313 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
392165 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6305609 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2803403 usd
CY2023Q1 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-858920 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
595502 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3824497 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3824497 usd
CY2023Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension
-561466 usd
CY2023Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-690406 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
466429 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4609940 usd
us-gaap Net Income Loss
NetIncomeLoss
689185 usd
us-gaap Interest Income Operating
InterestIncomeOperating
770422 usd
us-gaap Interest Income Operating
InterestIncomeOperating
1307724 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
22125 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
57183 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
65850 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
58125 usd
MSSA Increase Decrease In Due To Sponsor
IncreaseDecreaseInDueToSponsor
247712 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
31980 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
143996 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-344341 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
400000 usd
MSSA Cash Withdrawn From Trust Account To Redeem Public Shares
CashWithdrawnFromTrustAccountToRedeemPublicShares
60089158 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-400000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2803403 usd
CY2023Q1 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-858920 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
595502 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3824497 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3824497 usd
CY2023Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension
-561466 usd
CY2023Q2 MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount
-690406 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
466429 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4609940 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4609940 usd
us-gaap Net Income Loss
NetIncomeLoss
689185 usd
us-gaap Net Income Loss
NetIncomeLoss
1061931 usd
us-gaap Interest Income Operating
InterestIncomeOperating
770422 usd
us-gaap Interest Income Operating
InterestIncomeOperating
1307724 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
22125 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
57183 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
65850 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
58125 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
31980 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
143996 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
400000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1319142 usd
MSSA Cash Withdrawn From Trust Account To Redeem Public Shares
CashWithdrawnFromTrustAccountToRedeemPublicShares
60089158 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-400000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58770016 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
400000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1485995 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
60089158 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
400000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-58603163 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-177488 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178652 usd
MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension
1225152 usd
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
36684240 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35359088 usd
CY2022Q2 MSSA Proceeds From Ipo And Private Placement
ProceedsFromIpoAndPrivatePlacement
115682250 usd
CY2024Q2 MSSA Working Capital Deficit
WorkingCapitalDeficit
-3480609 usd
CY2023Q4 MSSA Working Capital Deficit
WorkingCapitalDeficit
-2844642 usd
CY2024Q2 MSSA Working Capital Deficit
WorkingCapitalDeficit
-3480609 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-400000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58770016 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
400000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1485995 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
60089158 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
400000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-58603163 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-177488 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178652 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1164 usd
MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension
1225152 usd
MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension
2868468 usd
CY2022Q2 MSSA Proceeds From Ipo And Private Placement
ProceedsFromIpoAndPrivatePlacement
115682250 usd
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
36684240 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35359088 usd
CY2024Q2 MSSA Working Capital Deficit
WorkingCapitalDeficit
-3480609 usd
CY2023Q4 MSSA Working Capital Deficit
WorkingCapitalDeficit
-2844642 usd
CY2024Q2 MSSA Working Capital Deficit
WorkingCapitalDeficit
-3480609 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zEC1BvJVUOfa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zpdtCF2svWL">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58770016 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
400000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1485995 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
60089158 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
400000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-58603163 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-177488 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178652 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1164 usd
MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension
1225152 usd
MSSA Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension
SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension
2868468 usd
CY2022Q2 MSSA Proceeds From Ipo And Private Placement
ProceedsFromIpoAndPrivatePlacement
115682250 usd
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
36684240 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35359088 usd
CY2022Q2 MSSA Proceeds From Ipo And Private Placement
ProceedsFromIpoAndPrivatePlacement
115682250 usd
CY2024Q2 MSSA Working Capital Deficit
WorkingCapitalDeficit
-3480609 usd
CY2023Q4 MSSA Working Capital Deficit
WorkingCapitalDeficit
-2844642 usd
CY2024Q2 MSSA Working Capital Deficit
WorkingCapitalDeficit
-3480609 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zEC1BvJVUOfa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zpdtCF2svWL">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zEC1BvJVUOfa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zpdtCF2svWL">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
466313 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
770422 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
690406 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1549326 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
448804 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1307724 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
466313 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
925152 usd
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
311583 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
770422 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
690406 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1549326 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
448804 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1307724 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2022Q3 MSSA Share Repurchase Program Excise Tax Percentage
ShareRepurchaseProgramExciseTaxPercentage
0.01 pure
CY2023Q3 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
2436497 shares
us-gaap Net Income Loss
NetIncomeLoss
689185 usd
us-gaap Net Income Loss
NetIncomeLoss
1061931 usd
CY2024Q2 MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
150000 usd
CY2023Q2 MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
561466 usd
MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
300000 usd
MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
1319142 usd
CY2024Q2 MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
466313 usd
CY2023Q2 MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
690406 usd
MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
925152 usd
MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
1549326 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-224148 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-785443 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-535967 usd
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
311583 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154730 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
690406 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1549326 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
448804 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1307724 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
241602 usd
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2022Q3 MSSA Share Repurchase Program Excise Tax Percentage
ShareRepurchaseProgramExciseTaxPercentage
0.01 pure
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
466429 usd
us-gaap Net Income Loss
NetIncomeLoss
689185 usd
us-gaap Net Income Loss
NetIncomeLoss
1061931 usd
CY2024Q2 MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
150000 usd
CY2023Q2 MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
561466 usd
MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
300000 usd
MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
1319142 usd
CY2024Q2 MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
466313 usd
CY2023Q2 MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
690406 usd
MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
925152 usd
MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
1549326 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-224148 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1806537 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zY7yCda9Hz6c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_za8Bp8HEAD98">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2022Q3 MSSA Share Repurchase Program Excise Tax Percentage
ShareRepurchaseProgramExciseTaxPercentage
0.01 pure
CY2023Q3 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
2436497 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5915000 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
392165 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
466429 usd
us-gaap Net Income Loss
NetIncomeLoss
689185 usd
us-gaap Net Income Loss
NetIncomeLoss
1061931 usd
CY2024Q2 MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
150000 usd
CY2023Q2 MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
561466 usd
MSSA Remeasurement To Redemption Value
RemeasurementToRedemptionValue
300000 usd
CY2024Q2 MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
466313 usd
CY2023Q2 MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
690406 usd
MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
925152 usd
MSSA Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares
InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares
1549326 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-224148 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-535967 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zY7yCda9Hz6c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_za8Bp8HEAD98">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zY7yCda9Hz6c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_za8Bp8HEAD98">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5885324 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
CY2023Q4 us-gaap Share Price
SharePrice
0.033
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2412260 shares
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5885324 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
CY2023Q4 us-gaap Share Price
SharePrice
0.033
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2412260 shares
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5885324 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
CY2023Q4 us-gaap Share Price
SharePrice
0.033
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2412260 shares
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
115000000 usd
MSSA Proceeds Allocated To Public Rights
ProceedsAllocatedToPublicRights
8510000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
5290000 usd
MSSA Allocation Of Offering Costs Related To Ordinary Shares
AllocationOfOfferingCostsRelatedToOrdinaryShares
5020172 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
86382792 usd
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
21287903 usd
MSSA Subsequent Measurement Of Class A Ordinary Shares Subject To Possible Redemption Interest Earned On Trust Account
SubsequentMeasurementOfClassAOrdinarySharesSubjectToPossibleRedemptionInterestEarnedOnTrustAccount
5549301 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
36634240 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
115000000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
5290000 usd
MSSA Allocation Of Offering Costs Related To Ordinary Shares
AllocationOfOfferingCostsRelatedToOrdinaryShares
5020172 usd
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
21287903 usd
MSSA Subsequent Measurement Of Class A Ordinary Shares Subject To Possible Redemption Interest Earned On Trust Account
SubsequentMeasurementOfClassAOrdinarySharesSubjectToPossibleRedemptionInterestEarnedOnTrustAccount
5549301 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
36634240 usd
CY2023Q1 MSSA Payment Of Extesnsion Fee
PaymentOfExtesnsionFee
383333 usd
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.033
CY2023Q1 MSSA Payment For Extension Fee
PaymentForExtensionFee
187155 usd
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
5885324 shares
CY2023Q4 MSSA Payment For Extension Fee
PaymentForExtensionFee
105680 usd
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.033
CY2023Q4 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
2412260 shares
CY2024Q2 MSSA Deferred Underwriting Commission
DeferredUnderwritingCommission
2875000 usd
CY2023Q4 MSSA Deferred Underwriting Commission
DeferredUnderwritingCommission
2875000 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
150000 usd
MSSA Monthly Payment Description
MonthlyPaymentDescription
The Company entered into the agreement with a retainer of $5,000 per month starting from April 1, 2022.
us-gaap Legal Fees
LegalFees
2500 usd
CY2024Q1 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
245000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3205000 shares
CY2022Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11500000 shares
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
115000000 usd
MSSA Proceeds Allocated To Public Rights
ProceedsAllocatedToPublicRights
8510000 usd
MSSA Allocation Of Offering Costs Related To Ordinary Shares
AllocationOfOfferingCostsRelatedToOrdinaryShares
5020172 usd
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
21287903 usd
MSSA Subsequent Measurement Of Class A Ordinary Shares Subject To Possible Redemption Interest Earned On Trust Account
SubsequentMeasurementOfClassAOrdinarySharesSubjectToPossibleRedemptionInterestEarnedOnTrustAccount
5549301 usd
CY2023Q1 MSSA Payment For Extension Fee
PaymentForExtensionFee
187155 usd
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
5885324 shares
CY2023Q4 MSSA Payment For Extension Fee
PaymentForExtensionFee
105680 usd
CY2023Q4 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
2412260 shares
CY2023Q4 MSSA Deferred Underwriting Commission
DeferredUnderwritingCommission
2875000 usd
us-gaap Professional Fees
ProfessionalFees
25000 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
150000 usd
MSSA Monthly Payment Description
MonthlyPaymentDescription
The Company entered into the agreement with a retainer of $5,000 per month starting from April 1, 2022.
us-gaap Legal Fees
LegalFees
2500 usd
CY2024Q1 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
245000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3205000 shares
CY2022Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11500000 shares
CY2023Q1 MSSA Payment Of Extesnsion Fee
PaymentOfExtesnsionFee
383333 usd
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.033
CY2023Q1 MSSA Payment For Extension Fee
PaymentForExtensionFee
187155 usd
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
5885324 shares
CY2023Q4 MSSA Payment For Extension Fee
PaymentForExtensionFee
105680 usd
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.033
CY2023Q4 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
2412260 shares
CY2024Q2 MSSA Deferred Underwriting Commission
DeferredUnderwritingCommission
2875000 usd
CY2023Q4 MSSA Deferred Underwriting Commission
DeferredUnderwritingCommission
2875000 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
150000 usd
MSSA Monthly Payment Description
MonthlyPaymentDescription
The Company entered into the agreement with a retainer of $5,000 per month starting from April 1, 2022.
us-gaap Legal Fees
LegalFees
2500 usd
CY2024Q1 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
245000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3205000 shares
CY2022Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11500000 shares

Files In Submission

Name View Source Status
0001493152-24-036960-index-headers.html Edgar Link pending
0001493152-24-036960-index.html Edgar Link pending
0001493152-24-036960.txt Edgar Link pending
0001493152-24-036960-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mssa-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mssa-20240630_cal.xml Edgar Link unprocessable
mssa-20240630_def.xml Edgar Link unprocessable
mssa-20240630_lab.xml Edgar Link unprocessable
mssa-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending